A -type lamins are intermediate filaments and major components of the nuclear lamina, a filamentous network underlying the inner nuclear membrane that provides structural and mechanical stability for the nucleus in nearly all differentiated cells. A-type lamins interact with heterochromatin and transcriptional regulators, highlighting their important role in chromatin organization, gene expression, and DNA repair.
occurring after puberty, whereas fat accumulates in the face and neck. Severe metabolic disturbances, such as insulin resistance, diabetes mellitus, hypertriglyceridemia, and low highdensity lipoprotein cholesterol, are associated with FPLD2. [5] [6] [7] Previous reports stressed that precocious vascular diseases (coronary heart disease, stroke, and peripheral arteritis) could also be part of the FPLD2 phenotype. 8, 9 Otherwise, patients with the Hutchinson-Gilford progeria syndrome (HGPS), a premature aging disorder linked to different LMNA mutations, display very severe and precocious atherosclerosis leading to early mortality, 10, 11 in the absence of classical cardiovascular risk factors. 12 The pathophysiological mechanisms involved in laminopathies associated with lipodystrophies are not fully understood. We, and others, have shown that FPLD2 is associated with abnormal prelamin-A accumulation, possibly because of the misrecognition of the mutated protein by the protease ZMPSTE24. 13, 14 Prelamin-A accumulation was associated with premature cellular senescence, mitochondrial dysfunctions, and oxidative stress in skin fibroblasts from patients with FPLD2. 14 HGPS result from the accumulation of progerin, a truncated and unprocessed form of prelamin-A that remains farnesylated. 15, 16 Interestingly, progerin is expressed in patients' vascular wall cells, 11, 17, 18 resulting in cellular senescence. 19 Progerin and farnesylated prelamin-A are now considered as dominantnegative toxins that disrupt nuclear lamina integrity and lead to induction and persistence of DNA double-strand breaks (DSBs). [20] [21] [22] [23] In accordance, decreasing the amount of farnesylated progerin reduced the premature aging phenotype associated with HGPS in vitro and in vivo in mice, [24] [25] [26] [27] and improved vascular stiffness in children with HGPS. 28 Endothelial cell dysfunction and senescence are considered as the first steps of vascular wall injury during the process of atherosclerosis. 29, 30 In endothelial cells, oxidative stress was shown to impair NO biodisponibility and to promote inflammation, leukocyte adhesion, and cellular senescence. [31] [32] [33] [34] In addition, DNA damages were observed in atherosclerotic lesions of patients with coronary heart diseases in vivo and linked with oxidative stress in vitro. 35 Thus, we hypothesized that abnormal accumulation of farnesylated p.R482-prelamin-A in the cells of patients with FPLD2 could result in endothelial cell dysfunction and senescence that, in addition to metabolic risk factors, could be important pathogenic events leading to premature atherosclerosis in these patients.
In the present study, we analyzed the clinical cardiovascular events in 19 adult patients with LMNA p.R482-linked FPLD2, which highlighted their early and severe atherosclerosis. To determine whether FPLD2-associated LMNA mutation could directly induce endothelial defects, we overexpressed wild-type (WT) or FPLD2-associated p.R482W-prelamin-A in human coronary artery endothelial cells (HCAECs) in primary culture. p.R482W-prelamin-A in endothelial cells and patients' fibroblasts was abnormally retained at the nuclear envelope. We also show, for the first time, that exogenous expression of p.R482W, but not WT-prelamin-A, resulted in endothelial dysfunction, DNA DSBs, and cellular senescence. Pravastatin, which decreases prelamin-A farnesylation, improved these in vitro defects, suggesting that accumulation of mutated and farnesylated prelamin-A could participate in FPLD2-associated premature atherosclerosis.
Patients and Methods
Details about patients and methods are available in the online-only Supplement.
Results

LMNA p.R482W/Q Patients Displayed Early and Severe Atherosclerosis
We analyzed cardiovascular and metabolic features of 19 consecutive patients from 14 unrelated pedigrees, aged >30 years, with FPLD2-associated LMNA p.R482W/Q mutations (Table) .
FPLD2 patients had a mean age of 49.5 years, and a mean body mass index of 23.8 kg/m 2 . Diabetes mellitus was present in 84% of cases and was generally controlled with a mean HbA1c of 7.5%. Dyslipidemia was found in 94% of patients. The mean level of fasting triglycerides was increased (4.3 mmol/L±0.7), and that of high-density lipoprotein cholesterol (0.9 mmol/L±0.1) and apolipoprotein A1 (1.1 g/L±0.1) decreased. The mean concentration of low-density lipoprotein cholesterol was 2.5 mmol/L with apolipoprotein B at 0.9 g/L±0.1. Hypertension or antihypertensive treatment was referred in 41% of cases.
LMNA p.R482W/Q patients showed a very high prevalence of symptomatic atherosclerosis at early age, as attested by cardiovascular events in 13 of them (68%), occurring before age 45 in 62% of cases. The clinical and biological characteristics of the patients with cardiovascular events are given in the 
Overexpression of p.R482W Prelamin-A Led to Defects in Prelamin-A Maturation and in Nuclear Shape Abnormalities
To determine the effects of p.R482W LMNA mutations on endothelial cells, we transiently transduced HCAECs with adenoviral vectors containing Flag-tagged WT or p.R482W-prelamin-A cDNA. Flag protein expression, analyzed 72 hours after transduction, was similar whatever the construction ( Figure 1A ). We observed a 2.5-fold increased expression As previously observed in patients' skin fibroblasts, 14 p.R482W LMNA mutation altered prelamin-A maturation, as shown by abnormal prelamin-A accumulation, whereas overexpressed WT-prelamin-A was properly processed to mature lamin-A ( Figure 1B ). This accumulation could result from a slower maturation rate as compared with WT-prelamin-A, as demonstrated in the skin fibroblasts of the patients with FPLD2 ( Figure IB in the online-only Data Supplement).
In transduced endothelial cells, overexpressed WT and mutated lamin-A localized to the nucleus. However, although cells overexpressing Flag-WT lamin-A showed regularly shaped nuclei, overexpression of p.R482W-prelamin-A led to misshapen nuclei, with nuclear blebs and nuclear envelope invaginations ( Figure 1C ). Interestingly, although WT exogenous lamin-A was distributed within the nucleoplasm and the nuclear rim, p.R482W-prelamin-A was mostly localized at the nuclear periphery, as determined by the nuclear distribution of Flag fluorescence ( Figure 1D ). A similar abnormal lamin-A distribution was observed in patients' skin fibroblasts bearing the LMNA p.R482W mutation ( Figure IC in the online-only Data Supplement). As it is known that lipid groups increase the anchoring of lamins to the nuclear envelope, 36 this result suggests that p.R482W-prelamin-A remained farnesylated.
p.R482W but Not WT-Prelamin-A Expression Led to Endothelial Dysfunction With Increased Inflammation and Peripheral Blood Mononuclear Cells Adhesion to HCAECs
Endothelial dysfunction, during atherosclerosis process, is characterized by a reduced bioavailability of NO, produced by endothelial NO synthase (eNOS), and a proinflammatory status. 30 p.R482W but not WT-prelamin-A overexpression was associated with a marked decreased expression of eNOS both at the mRNA and protein levels (Figure 2A ; Figure IIA in the online-only Data Supplement). Accordingly, NO production was impaired in p.R482W prelamin-A overexpressing Figure 2C ). We also observed that p.R482W but not WT-prelamin-A expression increased the mRNA expression and secretion of the cell adhesion molecules ICAM-1 and vascular cell adhesion molecule-1 (≈2-fold increase versus WT; Figure IIC in the online-only Data Supplement; Figure 2D ). To assess the functional consequences of the proadhesive and proinflammatory state induced by p.R482W-prelamin-A, we performed an adhesion assay of human peripheral blood mononuclear cells (PBMCs), isolated from healthy donors, to transduced HCAECs. The number of adherent PBMCs to p.R482W but not WT-prelamin-A overexpressing HCAECs was increased ( Figure 2E ; Figure IID in the online-only Data Supplement).
These results suggested that p.R482W mutated prelamin-A directly induced a proinflammatory and proadhesive state of endothelial cells, which could participate to the recruitment of PBMCs to the vascular wall.
p.R482W but Not WT-Prelamin-A Expression Led to Increased Oxidative Stress, Accumulation of DNA DSBs, and Early Senescence in HCAECs
As oxidative stress promotes endothelial dysfunction, 32 we measured the production of reactive oxygen species (ROS) and the mRNA expression of cell stress markers. p.R482W but not WT-prelamin-A overexpression led to increased ROS production (1.7-fold increase versus WT; Figure 3A ) and C/ EBP-homologous protein 10, cAMP-dependent transcription factor-3 and -4 (ATF-3, ATF-4) mRNA expression ( Figure 3B ; Figure IIIA in the online-only Data Supplement).
Because oxidative stress could induce DNA damages, 35 we evaluated the number of transduced HCAECs expressing the phosphorylated histone γ-H2AX, which is recruited after the induction of DNA DSBs. 37 γ-H2AX foci were observed in 10% to 12% of control and WT-prelamin-A overexpressing cells, but in 39% of cells overexpressing p.R482W-prelamin-A ( Figure 3C ; Figure Figure 3D ), which are cell cycle arrest proteins activated during DNA DSBs response. 38 Finally, senescence-activated β-galactosidase activity was enhanced in p.R482W but not in WT-prelamin-A expressing endothelial cells ( Figure 3E ).
Prelamin-A Farnesylation Is a Major Actor in LMNA p.R482W-Induced Endothelial Dysfunction
We then evaluated whether the farnesylation status of p.R482W-prelamin-A was involved in endothelial dysfunction by treating HCAECs in vitro with pravastatin. Statins are known to block the synthesis of farnesyl groups, thus inhibiting prelamin-A farnesylation and its further proteolytic maturation. 27 As expected, pravastatin increased the level of prelamin-A in WT and p.R482W-prelamin-A overexpressing HCAECs ( Figure 4A ). Moreover, pravastatin reduced the amount of p.R482W-prelamin-A present at the nucleus periphery and increased its amount in the nucleoplasm ( Figure 4B ). The nuclear distribution of pravastatin-treated p.R482W-prelamin-A was no longer different from that of nontreated WT-lamin A ( Figure 1D ). These data strongly support our hypothesis that overexpressed p.R482W-prelamin-A was farnesylated and remained tightly associated with the nuclear membrane. When its farnesylation was impaired by pravastatin, it was partly dissociated from the nuclear envelope.
Pravastatin prevented both oxidative stress and accumulation of DNA DSBs induced by p.R482W-prelamin-A in vitro ( Figure 4C and 4D) . Moreover, pravastatin decreased the p.R482W-prelamin-A-induced endothelial secretion of ICAM-1 and inflammatory markers (IL-6, IL-8, and monocyte chemoattractant protein-1; Figure 4E and 4F). In cells overexpressing WT-prelamin A, pravastatin was devoid of any effect on these parameters.
Altogether, these data suggested that LMNA p.R482W mutation induced farnesylated prelamin-A accumulation, which led to oxidative stress, DNA damages, and inflammation, and thus contributed to endothelial cell dysfunction.
Antioxidant Treatment Improved Adverse Effects Induced by p.R482W-Prelamin-A Overexpression
We then investigated the contribution of oxidative stress to LMNA p.R482W-induced endothelial dysfunction. As expected, treatment with the antioxidant molecule N-acetyl cysteine reversed ROS production ( Figure 5A ) and mRNA expression of the cell stress marker C/EBP-homologous protein 10 induced by p.R482W-prelamin-A ( Figure 5B) . Importantly, N-acetyl cysteine also reduced the secretion of IL-6, IL-8, and monocyte chemoattractant protein-1 ( Figure 5C ) and of ICAM-1 and vascular cell adhesion molecule-1 induced by p.R482W-prelamin-A ( Figure 5D ). N-acetyl cysteine treatment had no significant effect on both ROS production and inflammatory secretions in WT-prelamin-A overexpressing cells.
The occurrence of DNA DSBs was evaluated after longterm antioxidant treatment with reduced S-glutathione. Reduced S-glutathione significantly prevented the occurrence of DNA DSBs in p.R482W-prelamin-A-overexpressing HCAECs ( Figure 5E ), suggesting that oxidative stress contributed to DNA damages.
Taken together, these data suggest that oxidative stress, secondary to accumulation of farnesylated p.R482W-prelamin-A, induced endothelial dysfunction, DNA damages, and senescence.
Discussion
In the present study, we analyzed the cardiometabolic features of 19 patients with FPLD2-associated LMNA p.R482W/Q mutations and confirmed the high prevalence of atherosclerotic cardiovascular diseases, which occurred before the age of 45 for most of them.
Thus, we explored the hypothesis of a direct role of LMNA p.R482W mutation on endothelial cells, which dysfunction is considered as an early important step toward atherosclerosis. We observed that overexpressed p.R482W-prelamin-A directly triggered endothelial dysfunction and senescence, which could result from the accumulation of farnesylated mutated prelamin-A and increased oxidative stress. These data give new mechanisms concerning the pathophysiology of LMNA-linked atherosclerotic complications.
Although patients with FPLD2 frequently presented proatherogenic features, such as diabetes mellitus, high triglycerides levels, and low high-density lipoprotein cholesterol with decreased apolipoprotein A1, they did not show high levels of low-density lipoprotein cholesterol and apolipoprotein B. This suggested that early atherosclerosis is part of FPLD2 phenotype and could be, at least in part, linked to a direct effect of the mutation, in addition to classical cardiovascular risk factors.
We also observed that patients with FPLD2, as compared with controls, had higher plasma levels of high-sensitive C-reactive protein, IL-6, and ICAM-1, all markers linked with cardiovascular risk in the general population. Interestingly, IL-6 and ICAM-1 are secreted by endothelial cells, and C-reactive protein production is enhanced by IL-6. [39] [40] [41] [42] Conversely, vascular cell adhesion molecule-1, which was not significantly increased in patients with FPLD2, was not clearly associated with increased incidence of coronary heart disease or stroke. 39, 41 To evaluate the effect of the p.R482W mutation in endothelial cells, we used HCAECs overexpressing either WT-or p.R482W-prelamin-A. Although WT-prelamin-A was correctly processed, p.R482W LMNA mutations resulted in abnormal prelamin-A accumulation, as previously shown in patients' fibroblasts. 13, 14 Prelamin-A accumulation could result from a delay in the maturation process, as demonstrated in the skin fibroblasts of the patients with FPLD2. Remarkably, prelamin-A processing rate is also slower in fibroblasts issued from patients with HGPS. 43 Interestingly, p.R482W-prelamin-A had a peculiar nuclear localization, being predominantly present at the nuclear envelope. We also confirmed this mislocalization in patients' fibroblasts. The effect of the farnesylation inhibitor pravastatin, which prevented the abnormal nuclear distribution of p.R482W-prelamin-A in HCAECs, suggests that p.R482W-prelamin-A remained farnesylated, its farnesyl group acting as an anchor to the nuclear envelope. 36 During the atherosclerosis process, early alterations include endothelial dysfunction with a reduced bioavailability of NO, produced by eNOS. 30 Indeed, in human atherosclerotic plaques, eNOS expression and NO production are decreased. 44 In HCAECs overexpressing p.R482W, but not WT-prelamin-A, we observed a markedly diminished eNOS expression and NO production. A previous study reported a decreased eNOS expression in senescent endothelial cells, attributable to telomere shortening. Accordingly, transfection of the telomerase catalytic subunit significantly prevented endothelial dysfunction associated with cellular senescence, thus improving eNOS expression and activity. 29 In our study, the early senescence of p.R482W prelamin-A overexpressing HCAECs could partly explain the diminution of eNOS expression and NO production.
We also showed an increased expression and secretion of chemokines, cytokines, and cell-surface adhesion molecules leading to increased adhesion of PBMCs to HCAECs overexpressing p.R482W but not WT-prelamin-A. Taken as a whole, these data indicate that p.R482W-prelamin-A led to endothelial dysfunction in vitro.
Oxidative damage was detectable in >90% of cells in atherosclerotic plaques 45 and was shown to play a major role in endothelial dysfunction during the atherosclerosis process. 32 We observed that ROS production and expression of cell stress markers C/EBP-homologous protein 10, ATF-3, and ATF-4 were enhanced in HCAECs overexpressing p.R482W-prelamin-A.
Oxidative stress is known to induce an array of DNA adducts and single-and double-stranded breaks. 35 DNA DSBs activate the DNA repair pathways, including serine phosphorylation of histone H 2 AX. Failure of DNA repair results in increased expression of p53 and of cell cycle arrest checkpoint kinases. 38 DNA damages and increased H 2 AX phosphorylation were observed in atherosclerotic plaques. 46 We show here, for the first time, that overexpression of p.R482W-prelamin-A led to an increased number of DNA DSBs, revealed by γH 2 AX phosphorylation, in endothelial cells. We confirmed this result in skin fibroblasts from patients with FPLD2. Accordingly, expression of p53 and of the cell cycle blockers p16
INK4a and p21 WAF1 was increased in HCAECs overexpressing p.R482W-prelamin-A, resulting in cellular senescence, which also contributes to atherosclerosis. 29 Farnesylated prelamin-A was shown to induce vascular smooth muscle cells impairment, with DNA DSBs and senescence. 22 Our group previously reported that HIV protease inhibitors, known to inhibit ZMPSTE24, 47 induced an accumulation of farnesylated prelamin-A in endothelial cells and that the inhibition of prelamin-A farnesylation by pravastatin treatment improved endothelial dysfunction in this model. 33 We demonstrated here that pravastatin treatment in vitro also decreased the amount of p.R482W farnesylated prelamin-A, improved endothelial dysfunction and oxidative stress, and reduced the occurrence of DNA damages in HCAECs. Moreover, we observed that antioxidant treatments reduced the secretion of inflammatory and adhesion molecules and decreased DNA DSBs in HCAECs overexpressing p.R482W-prelamin-A.
Our study suggests that endothelial cell inflammation, proadhesive and senescent states were mediated by oxidative stress in cells expressing farnesylated p.R482W-prelamin-A. A hypothetical scheme of the pathophysiological mechanisms leading from LMNA p.R482 mutations to endothelial dysfunction is proposed in Figure 6 .
Our study has some limitations. The model of lamin-A overexpression does not reproduce the 1:1 ratio of mutated versus WT-lamin expected in heterozygous cells from patients with FPLD2. However, under our overexpression conditions, we had a 2.5-fold increased lamin-A level leading to a stoichiometry of ≈1.5 exogenous for 1 endogenous lamin-A. Furthermore, cultured endothelial cells are not submitted to their physiological environment and, in particular, to the blood flow. Because A-type lamins are involved in mechanotransduction signaling, endothelial responses to blood flow could also be altered in patients' cells. 48 In addition, the effect of metabolic disturbances, which contribute to endothelial dysfunction in atherosclerosis, was not evaluated.
In conclusion, we show here that severe atherosclerosis observed in FPLD2 could partly originate from primary endothelial dysfunction directly induced by LMNA mutations, in addition to classical cardiovascular risk factors. Our results support a role for farnesylated p.R482W-prelamin-A in the early atherosclerosis observed in patients with FPLD2.
